Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report)'s share price traded up 3.3% during trading on Friday . The stock traded as high as $27.46 and last traded at $26.42. 116,407 shares were traded during mid-day trading, a decline of 40% from the average session volume of 192,576 shares. The stock had previously closed at $25.57.
Chugai Pharmaceutical Price Performance
The stock has a market capitalization of $86.95 billion, a P/E ratio of 34.31 and a beta of 0.76. The firm has a 50-day simple moving average of $26.19 and a 200 day simple moving average of $23.77.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.19 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. The firm had revenue of $1.89 billion during the quarter. Sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current fiscal year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
